Search

New Target, Drug Potential Found for Colon Cancer

New Target, Drug Potential Found for Colon Cancer

In a study published online January 31st in the Journal of the National Cancer Institute, researchers from the Institute of Cancer Research (ICR) found that Sprycel, known generically as dasatinib and already used in other cancers, reduced bowel cancer cell growth in the lab by blocking the effects of an enzyme called lysyl oxidase, or LOX.